Publication:

Journal of Virology 1671-1683

Author(s):

Boonnak, Kobporn., Dambach, Kaitlyn M., et al.

Quansys Products Used:

Human Chemokine (9-Plex)

Abstract:

Antibody-dependent enhancement (ADE) is implicated in severe, usually secondary, dengue virus (DV) infections. Preexisting heterotypic antibodies, via their Fc-gamma receptor (FcγR) interactions, may increase disease severity through enhanced target cell infection. Greater numbers of infected target cells may contribute to higher viremia and excess cytokine levels often observed in severe disease. Monocytes, macrophages, and immature and mature dendritic cells (DC) are considered major cellular targets of DV. Apheresis of multiple donors allowed isolation of autologous primary myeloid target cell types for head-to-head comparison of infection rates, viral output, and cytokine production under direct infection (without antibody) or ADE conditions (with antibody). All studied cell types except immature DC supported ADE. All cells undergoing ADE secreted proinflammatory cytokines (interleukin-6 [IL-6] and tumor necrosis factor alpha [TNF-α]) at enhancement titers, but distinct cell-type-specific patterns were observed for other relevant proteins (alpha/beta interferon [IFN-α/β] and IL-10). Macrophages produced type I interferons (IFN-α/β) that were modulated by ADE. Mature DC mainly secreted IFN-β. Interestingly, only monocytes secreted IL-10, and only upon antibody-enhanced infection. While ADE infection rates were remarkably consistent in monocytes (10 to 15%) across donors, IL-10 protein levels varied according to previously described regulatory single nucleotide polymorphisms (SNPs) in the IL-10 promoter region. The homozygous GCC haplotype was associated with high-level IL-10 secretion, while the ACC and ATA haplotypes produced intermediate and low levels of IL-10, respectively. Our data suggest that ADE effects are cell type specific, are influenced by host genetics, and, depending on relative infection rates, may further contribute to the complexity of DV pathogenesis.

As researchers and problem solvers ourselves, we understand the value of sound data. We are proud to be a part of research that can better the world. We value the relationships, partnerships, and friendships that we have built with the people who trust and use our technology. We are committed to building these relationships. You can count on us to answer the phone and take time to thoroughly address questions or concerns about any of our products. In an industry that is reputed for grandiose claims, we trust that our quality standards and our customer service set us apart from the competition. If you’re happy with our products or if you think we can do something better, we hope you will let us know.

1-888-782-6797

info@quansysbio.com

365 North 600 West Logan, UT 84321